A Comparative Study of Retrospective Outcomes Including Efficacy of Therapy Between Advanced Immunotherapy and Classical Immunochemotherapy in Relapsed/Refractory Lymphoma
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 2,500
- 试验地点
- 1
- 主要终点
- Comparison of Survival Periods Among Groups Comparison of Survival Periods Among Groups
研究概览
简要总结
The goal of this retrospective study is to compare between the case cohort and control cohort.
The case cohort consists of lymphoma patients treated with novel immunotherapy regimen including Chimeric antigen receptor T cell therapy, bispecfic antibody, and/or antibody-drug conjugate.
The control cohort consists of lymphoma patients who received conventional chemotherapy as standard-of-care
The main question[s] it aims to answer are:
- Survival times
- Response outcomes
详细描述
-
Primary endpoints Comparison of survival time by treatment between two groups
-
Secondary endpoints 2.1 Comparison of progression-free survival between two groups 2.2 Comparison of response rates between two groups 2.3 Comparison of input medical costs between two groups.
-
Study subjects: Patients treated for lymphoma at Yeouido St. Mary's Hospital and Seoul St. Mary's Hospital (Both are located on Seoul, Korea) between May 2009 and June 2023.
-
Selection criteria: 3.1 Patients diagnosed with malignant lymphoma at Catholic Yeouido St. Mary's Hospital and Seoul St. Mary's Hospital between May 2009 and June 2023.
3.2 Age 19 or older. 3.3 Patients who treated with salvage chemotherapy for the relapsed/refractory lymphoma.
- Exclusion criteria: 4.1 Patients suffering from acute leukemia. 4.2 Patients additionally diagnosed with solid cancer (colon cancer, lung cancer, stomach cancer, etc.) during treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with malignant lymphoma at Catholic Yeouido St. Mary's Hospital and Seoul St. Mary's Hospital between May 2009 and June
- •Age 19 or older.
- •Anti-cancer salvage chemotherpay for the treatment of relapsed/refractory lymphoma.
排除标准
- •Patients suffering from acute leukemia.
- •Patients additionally diagnosed with solid cancer (colon cancer, lung cancer, stomach cancer, etc.) during treatment.
研究组 & 干预措施
T cell engager
干预措施: Immunotherapy (Drug)
Standard-of-care
干预措施: Immunotherapy (Drug)
结局指标
主要结局
Comparison of Survival Periods Among Groups Comparison of Survival Periods Among Groups
时间窗: Time Frame: Up to 2 years
overall survival
次要结局
- Comparison of Progression-Free Survival Periods(Time Frame: Up to 2 years)
研究者
Sung-Soo Park
clinical professor
Seoul St. Mary's Hospital